SC Ropharma (BSE:RPH) Research & Development: lei0 Mil (TTM As of Dec. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSE:RPH SC Ropharma SA BSE:RPH
66 GF Score
Price lei0.20
View Full Analysis

What is SC Ropharma Research & Development?

SC Ropharma BSE:RPH 66 Research & Development is lei0 Mil as of Dec. 2024. GuruFocus rates BSE:RPH with a GF Score™ of 66/100.

Research & Development is the aggregate amount of research and development expenses during the year. SC Ropharma's Research & Development for the six months ended in Dec. 2024 was lei0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 was lei0 Mil.

SC Ropharma  (BSE:RPH) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

SC Ropharma Research & Development Related Terms

SC Ropharma Research & Development Historical Data

* Premium members only.

The historical data trend for SC Ropharma's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SC Ropharma Research & Development Chart

SC Ropharma Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

SC Ropharma Semi-Annual Data
Dec13 Dec14 Dec15 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BSE:RPH
66GF Score
SC Ropharma SA BSE:RPH
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SC Ropharma Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was lei0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of lei0 Mil mean?
SC Ropharma (BSE:RPH) has a Research & Development of lei0 Mil as of Dec. 2024. Research and development expense is the total cost for research and development activities. View historical data on SC Ropharma and its competitors.
Is SC Ropharma's Research & Development too high?
SC Ropharma's current Research & Development is lei0 Mil. Overall, SC Ropharma has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does SC Ropharma's Research & Development compare to competitors?
SC Ropharma's Research & Development of lei0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on SC Ropharma and its competitors. SC Ropharma's current Research & Development is lei0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SC Ropharma stock overvalued right now?
SC Ropharma (BSE:RPH) has a current Research & Development of lei0 Mil. The current Research & Development is lei0 Mil. SC Ropharma's overall GF Score™ is 66/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For SC Ropharma (BSE:RPH), the current Research & Development is lei0 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SC Ropharma Business Description

Address Strada Iuliu Maniu Nr. 55, ETAJ 1, Brasow, ROU, 500091
SC Ropharma SA is engaged in the production, distribution, and Retail sale of pharmaceutical products in specialized stores. Its product portfolio comprises over 50 products in the form of tablets, powders, capsules, and syrups covering 21 therapeutic areas.
66GF Score

Get the complete analysis for BSE:RPH

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

lei0.20
Price